The work on this project was directed towards the development of a phase I, randomized, placebo-controlled, dose-escalation study of a multicomponent HIV-1 adenoviral vector vaccine. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to HIV-1. The proposed protocol design is to enroll subjects who will be randomly assigned to vaccine or PBS control injections. If there are no significant toxicities, dose escalation will be initiated.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005041-01
Application #
6696472
Study Section
(VPP)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cheng, Cheng; Gall, Jason G D; Kong, Wing-pui et al. (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3:e25
Sheets, R L (2006) Adventitious agent test methods. Dev Biol (Basel) 123:135-45; discussion 183-97
Sheets, Rebecca (2006) Assaying potency of novel vaccines. October 11-12, 2005, Bethesda, MD, USA. Expert Rev Vaccines 5:315-8
Butman, B T; Lizonova, A; Brough, D E et al. (2006) Comprehensive characterization of the 293-ORF6 cell line. Dev Biol (Basel) 123:225-33; discussion 265-6